|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Four cases of small lymphocyte-predominant benign PE from patients without history of lymphoma were examined and were all negative for MYD88 L265P mutation.
|
31556196 |
2019 |
|
rs2230926
|
|
|
0.040 |
GeneticVariation |
BEFREE |
However, the rs2230926 variant allele seems to confer a higher risk to develop lymphoma in pSS patients, while in RA patients, the presence of RF resulted significantly associated with the variant allele.
|
31534975 |
2019 |
|
rs121913503
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The test evaluates the expression of 20 genes, including 17 markers relevant to T-cell immunology and lymphoma biopathology, one EBV-related transcript, and variants of RHOA (G17V) and IDH2 (R172K/T).
|
31488561 |
2019 |
|
rs1353428252
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The test evaluates the expression of 20 genes, including 17 markers relevant to T-cell immunology and lymphoma biopathology, one EBV-related transcript, and variants of RHOA (G17V) and IDH2 (R172K/T).
|
31488561 |
2019 |
|
rs1057519781
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
|
31177400 |
2019 |
|
rs3099844
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<i>HCP5</i> rs3099844 was associated with anti-SSA (<i>P</i> = 0.006, OR = 3.07) and anti-SSB (<i>P</i> = 0.005, OR = 2.66) antibodies, severity of focus score (<i>P</i> = 0.03, OR = 12), and lymphoma development (<i>P</i> = 0.002, OR = 7.23).
|
30882006 |
2019 |
|
rs2230926
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Increased prevalence of the rs2230926 mutant variant was detected in both SS-lymphoma and SS-nonlymphoma subgroups compared to HC (8.8% vs. 7.6% vs. 3.6%, <i>p</i> values: 0.04 and 0.03, respectively) in association with higher IgM, LDH serum levels, and PB <i>Bcl-XL</i> transcripts but lower leucocyte and neutrophil counts.
|
30662920 |
2018 |
|
rs138228187
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation <i>via</i> NF-κB mediated signaling in B-cells.
|
30381301 |
2019 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Suppressing IL-10 significantly reduced STAT3 activation in both MYD88 WT and MYD88 L265P m</spa</span>n>utant lymphomas</span>.
|
30253331 |
2018 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
|
30204732 |
2019 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With clinical trials regarding their efficacy rapidly expanding to NHLs, we also discuss potential combinations of immune checkpoint inhibitors with the described targeted chemotherapies of L265P signaling networks, and/or with the above immunological approaches as potential ways of targeting MYD88-mutated lymphomas in the future.
|
30203262 |
2018 |
|
rs2231231
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Accordingly, we analyzed the association between a single-nucleotide polymorphism locus of aquaporin 3 (rs2231231) and Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (EBVaNPC), lymphoma (EBVaL), and gastric carcinoma in China.
|
30110699 |
2018 |
|
rs1946518
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that IL-18 (rs1946518) and NFκB94 ins/del (rs28362491) contributed to lymphoma susceptibility and allele G in IL-18 was significantly associated with the risk of lymphoma.
|
29312552 |
2017 |
|
rs28362491
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that IL-18 (rs1946518) and NFκB94 ins/del (rs28362491) contributed to lymphoma susceptibility and allele G in IL-18 was significantly associated with the risk of lymphoma.
|
29312552 |
2017 |
|
rs2274084
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated GJB2 rs2274084 polymorphism in three types of tumors, including nasophoryngeal carcinoma (NPC), gastric cancer (GC) and lymphoma.
|
29103018 |
2018 |
|
rs2071286
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The significant relationship between rs2071286 and rs9461776 MAF and the increased risk for NHL, suggests their use as non-invasive markers to categorize patients at risk of lymphoma.
|
29069725 |
2017 |
|
rs9461776
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The significant relationship between rs2071286 and rs9461776 MAF and the increased risk for NHL, suggests their use as non-invasive markers to categorize patients at risk of lymphoma.
|
29069725 |
2017 |
|
rs397507444
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Αnalysis according to lymphoma subtype revealed increased frequency of c. 677C > T TT genotype and T allele, as well as reduced prevalence of the c. 1298A > C C allele in the pSS non-MALT group compared to controls and patients without NHL.
|
28779180 |
2017 |
|
rs1217691063
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Αnalysis according to lymphoma subtype revealed increased frequency of c. 677C > T TT genotype and T allele, as well as reduced prevalence of the c. 1298A > C C allele in the pSS non-MALT group compared to controls and patients without NHL.
|
28779180 |
2017 |
|
rs1805087
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results in this meta-analysis suggest no association between the MS A2756G polymorphism and lymphoma risk; however, the GG homozygous and G alleles could decrease the lymphoma risk in Caucasians.
|
28742198 |
2017 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy.
|
28405493 |
2017 |
|
rs1042752
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs1042752-located in the 3'-UTR of POU2AF1, which plays a vital role in lymphomagenesis-was significantly associated with lymphoma risk in a case-control study with 793 patients and 939 controls.
|
28345816 |
2017 |
|
rs11540652
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We previously showed that the HSP90 inhibitor ganetespib potently suppresses T-lymphoma initiation and progression and extends overall survival (OS) in hotspot knockin mice expressing the p53 gain-of-function mutants R175H and R248Q (mutp53) by 30-59%.
|
28300840 |
2017 |
|
rs28934578
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We previously showed that the HSP90 inhibitor ganetespib potently suppresses T-lymphoma initiation and progression and extends overall survival (OS) in hotspot knockin mice expressing the p53 gain-of-function mutants R175H and R248Q (mutp53) by 30-59%.
|
28300840 |
2017 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The MYD88 missense mutation c.794T>C, p.Leu265Pro, is found in patients with Waldenstörm's macroglobulinemia and lymphoma.
|
28042684 |
2017 |